19 completed, 5 terminated, 5 unknown, 2 active not recruiting. 36 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 36 | Completed 19, Terminated 5, Unknown 5, Active not recruiting 2, Recruiting 2, Enrolling by invitation 1, Not yet recruiting 1, Suspended 1 |
| Phase 1 | 6 | Completed 5, Unknown 1 |
Follow Bronchiectasis: new trials by email Literature Review of Bronchiectasis trials Research Report on Bronchiectasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis SAR445399, Placebo - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Suspended | Sanofi | 70 | 2026-06-08 | 2026-07-29 |
| Efficacy and Safety of Lifei Qingchang Granules for Stable Bronchiectasis Lifei Qingchang Granules, Placebo, Postural Drainage - Bronchiectasis | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Guangzhou Medical University | 150 | 2026-04-01 | 2026-04-13 |
| A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis GSK3862995B, Placebo - Bronchiectasis | Phase 2 | Recruiting | GlaxoSmithKline | 363 | 2025-10-30 | 2026-08-12 |
| COMBO Endoscopy Oropharyngeal Airway in Sedated Fiberoptic Bronchoscopy for Patients: A Simon Two-Stage Trial the COMBO Endoscopy Oropharyngeal Airway - Pulmonary Infection, Pulmonary Nodule | Phase 2 | Completed | Zhejiang University | 104 | 2025-06-23 | 2026-02-24 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis XH-S004 20 mg, XH-S004 40 mg, Placebo - Non-Cystic Fibrosis Bronchiectasis | Phase 2 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 234 | 2025-05-30 | 2026-09-25 |
| A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion HSK31858, Placebo - Asthma Bronchiale, Bronchiectasis | Phase 2 | Enrolling by invitation | Haisco Pharmaceutical Group Co., Ltd. | 309 | 2024-12-10 | 2025-02-20 |
| Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis Antibiotic monotherapy treatment and follow-up, Antibiotic bitherapy treatment and follow-up - Bronchiectasis | Phase 2 | Recruiting | Centre Hospitalier Intercommunal Creteil | 196 | 2024-09-15 | 2026-08-27 |
| A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™) BI 1291583, Placebo to BI 1291583 - Cystic Fibrosis, Bronchiectasis | Phase 2 | Completed | Boehringer Ingelheim | 22 | 2024-04-05 | 2026-06-23 |
| A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis Itepekimab (SAR440340), Placebo - Bronchiectasis | Phase 2 | Completed | Sanofi | 314 | 2024-02-20 | 2026-10-07 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis CHF6333, CHF6333 Placebo - Bronchiectasis | Phase 1 / Phase 2 | Completed | Chiesi Farmaceutici S.p.A. | 108 | 2023-11-29 | 2026-10-26 |
| Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine BI 1291583, Placebo matching BI 1291583 - Bronchiectasis | Phase 2 | Active not recruiting | Boehringer Ingelheim | 268 | 2023-09-08 | 2026-10-14 |
| Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough ARINA-1, Placebo - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Completed | Renovion, Inc. | 40 | 2022-10-03 | 2025-07-23 |
| A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis BI 1291583, Placebo - Bronchiectasis | Phase 2 | Completed | Boehringer Ingelheim | 322 | 2022-04-28 | 2026-07-28 |
| Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections BCG TICE Vaccine - Cystic Fibrosis, Bronchiectasis Adult | Phase 2 | Completed | Johns Hopkins University | 30 | 2021-04-28 | 2025-02-10 |
| COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2 RESP301 - COPD, Bronchiectasis | Phase 2 | Terminated | Thirty Respiratory Limited | 88 | 2021-03-01 | 2025-01-31 |
| Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis QBW251, Placebo - Bronchiectasis | Phase 2 | Terminated | Novartis Pharmaceuticals | 42 | 2021-02-02 | 2025-09-26 |
| Autologous Transplantation of Bronchial Basal Cells for Treatment of Bronchiectasis Bronchial basal cells (BBCs), Bronchoscopic airway clearance treatment （B-ACT） - Bronchiectasis | Phase 1 / Phase 2 | Completed | Ruijin Hospital | 37 | 2020-06-21 | 2023-12-05 |
| Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Bronchiectasis Roflumilast, Placebo oral tablet - Bronchiectasis Adult | Phase 2 | Unknown | University of Sao Paulo General Hospital | 30 | 2019-12-06 | 2020-01-13 |
| Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis S-1226 - Cystic Fibrosis, Bronchiectasis | Phase 2 | Unknown | SolAeroMed Inc. | 12 | 2019-08-08 | 2021-06-16 |
| The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases PC945, Placebo - Asthma, Respiratory Candidiasis | Phase 2 | Terminated | Pulmocide Ltd | 13 | 2018-11-15 | 2020-06-12 |
Showing 20 of 36. Sign in to see all of them.
Cystic Fibrosis (3) · Lung Diseases (3) · Pulmonary Disease, Chronic Obstructive (3) · Asthma (2) · Pseudomonas Infections (2) · Respiratory Tract Diseases (2) · Bronchitis, Chronic (1) · Fibrosis (1) · Hypoxia (1) · Respiration Disorders (1) · Respiratory Aspiration (1) · Respiratory Tract Infections (1)
Bronchial Diseases (36) · Respiratory Tract Diseases (34) · Pathological Conditions, Signs and Symptoms (7) · Lung Diseases (6) · Pathologic Processes (6) · Lung Diseases, Obstructive (5) · Chronic Disease (4) · Disease Attributes (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Digestive System Diseases (3) · Genetic Diseases, Inborn (3) · Infant, Newborn, Diseases (3) · Infections (3) · Pancreatic Diseases (3) · Bacterial Infections (2)
Azithromycin (1) · Aztreonam (1) · Ciprofloxacin (1) · Drainage, Postural (1) · Fluticasone (1) · Inhalation (1) · Lysine Acetyltransferase 5 (1) · Mannitol (1) · Melphalan (1) · N-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide (1) · N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide (1) · Roflumilast (1) · Saline Solution, Hypertonic (1) · Sodium Chloride (1) · Tobramycin (1)
Boehringer Ingelheim (3) · AstraZeneca (2) · Bayer (2) · Insmed Incorporated (2) · Novartis Pharmaceuticals (2) · Sanofi (2) · Syntara (2) · Belfast Health and Social Care Trust (1) · Centre Hospitalier Intercommunal Creteil (1) · Chiesi Farmaceutici S.p.A. (1) · Federal State Budgetary Institution, Pulmonology Scientific Research Institute (1) · Gilead Sciences (1) · GlaxoSmithKline (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Johns Hopkins University (1)
United Kingdom (17) · United States (12) · Spain (11) · Germany (10) · China (9) · Italy (9) · France (7) · Poland (7) · Australia (6) · Netherlands (6) · Belgium (5) · Canada (5) · Bulgaria (4) · Czechia (4) · Denmark (4)
Adam Hill, MD PhD (1) · Bengt Larsson,, M.B (1) · Carin Jorup (1) · Carlos Fernandez, MD (1) · Charles L Daley, MD (1) · Eva Polverino, MD (1) · Francesco Blasi, MD (1) · Gina Eagle, MD (1) · Huib Kerstjens, MD, PhD (1) · James D. Chalmers (1) · Kirill Zykov, Prof (1) · Mark Montgomery, MD (1) · Noah Lecthzin, MD, MHS (1)
PMID 39175217, PMID 23018904, PMID 23433769, PMID 23825784, PMID 24626872, PMID 29221370, PMID 31433997, PMID 32855225, PMID 32897034, PMID 37198686, PMID 37538173, PMID 39255990, PMID 39566467, PMID 39938076, PMID 40072449, PMID 41192693
2018 (2), 2023 (2), 2025 (2), 2009 (1), 2015 (1), 2017 (1)